Limosilactobacillus reuteri YLR001 Attenuates DSS-Induced Colitis in Association with Notch-Related Macrophage Polarization and the Gut Microbiota–Bile Acid Remodeling

Background: Inflammatory bowel disease (IBD) is characterized by impaired intestinal barrier function, dysregulated immune responses, and gut microbial imbalance. Although Limosilactobacillus reuteri exerts strain-dependent anti-inflammatory effects, the mechanisms linking its immunomodulatory activity to microbial and metabolic homeostasis remain unclear. Objective: This study investigated the protective effects of yak-derived Limosilactobacillus reuteri YLR001 against DSS-induced colitis, focusing on Notch-associated macrophage polarization and microbiota-related bile acid metabolism. Methods: DSS-induced colitis mice and LPS-stimulated RAW 264.7 macrophages were used to evaluate disease severity, epithelial barrier integrity, inflammatory responses, macrophage polarization, and Notch1/Jagged1/Hes1 signaling. DAPT, a γ-secretase inhibitor, was used as a pharmacological probe of Notch-associated responses. Gut microbiota and cecal metabolites were characterized by 16S rRNA sequencing and untargeted metabolomics, followed by microbiota–metabolite correlation analysis. Results: YLR001 alleviated body-weight loss, colonic shortening, disease activity, splenomegaly, and histological damage, while restoring ZO-1, Occludin, Claudin-1, and MUC2 expression. It suppressed the pro-inflammatory macrophage phenotype, reducing iNOS and increasing Arg-1, CD206, and CD163, accompanied by lower IL-1β, IL-6, and TNF-α and higher IL-10 levels. These changes coincided with reduced expression of Notch1, Jagged1, and Hes1, whereas DAPT elicited comparable macrophage responses. In addition, YLR001 partially restored microbial homeostasis and modulated bile acid-related metabolic pathways. Correlation analysis further associated responsive taxa and metabolites with epithelial barrier and inflammatory phenotypes. Conclusions: YLR001 attenuates experimental colitis with associated changes in macrophage responses and the intestinal microbial–metabolic environment, supporting its potential as a strain-specific probiotic candidate.

Authors

Institutions

Publication Details

Journal
Foods
Published
2026-11-18
DOI
https://doi.org/10.3390/foods15224143
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Limosilactobacillus reuteri YLR001 Attenuates DSS-Induced Colitis in Association with Notch-Related Macrophage Polarization and the Gut Microbiota–Bile Acid Remodeling

Xiaofei Ma, Huachun Pan, Tian Niu, Junjie Hu et al.
5 links
Foods
Inflammatory Bowel Disease
article

Limosilactobacillus reuteri YLR001 Attenuates DSS-Induced Colitis in Association with Notch-Related Macrophage Polarization and the Gut Microbiota–Bile Acid Remodeling

Xiaofei Ma, Huachun Pan, Tian Niu, Junjie Hu, Tao Li, Lihong Zhang, Yuting Zou, Jianchun Sun, Zhenxing Yan, Yue Gao
article en

Abstract

Background: Inflammatory bowel disease (IBD) is characterized by impaired intestinal barrier function, dysregulated immune responses, and gut microbial imbalance. Although Limosilactobacillus reuteri exerts strain-dependent anti-inflammatory effects, the mechanisms linking its immunomodulatory activity to microbial and metabolic homeostasis remain unclear. Objective: This study investigated the protective effects of yak-derived Limosilactobacillus reuteri YLR001 against DSS-induced colitis, focusing on Notch-associated macrophage polarization and microbiota-related bile acid metabolism. Methods: DSS-induced colitis mice and LPS-stimulated RAW 264.7 macrophages were used to evaluate disease severity, epithelial barrier integrity, inflammatory responses, macrophage polarization, and Notch1/Jagged1/Hes1 signaling. DAPT, a γ-secretase inhibitor, was used as a pharmacological probe of Notch-associated responses. Gut microbiota and cecal metabolites were characterized by 16S rRNA sequencing and untargeted metabolomics, followed by microbiota–metabolite correlation analysis. Results: YLR001 alleviated body-weight loss, colonic shortening, disease activity, splenomegaly, and histological damage, while restoring ZO-1, Occludin, Claudin-1, and MUC2 expression. It suppressed the pro-inflammatory macrophage phenotype, reducing iNOS and increasing Arg-1, CD206, and CD163, accompanied by lower IL-1β, IL-6, and TNF-α and higher IL-10 levels. These changes coincided with reduced expression of Notch1, Jagged1, and Hes1, whereas DAPT elicited comparable macrophage responses. In addition, YLR001 partially restored microbial homeostasis and modulated bile acid-related metabolic pathways. Correlation analysis further associated responsive taxa and metabolites with epithelial barrier and inflammatory phenotypes. Conclusions: YLR001 attenuates experimental colitis with associated changes in macrophage responses and the intestinal microbial–metabolic environment, supporting its potential as a strain-specific probiotic candidate.

FoodsVol. 15(22)
Gansu Agricultural University (CN), Longyan University (CN)
National Natural Science Foundation of China
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon